Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Branford

Showing results (371-380 of 480) with videos related to

Pageof 48
Sort By:
Nature Communications|August 27, 2024
Neuromorphic overparameterisation and few-shot learning in multilayer physical neural networksKilian D Stenning, Jack C Gartside, Luca Manneschi, et al.
Leukemia Research|March 2, 2018
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift studyDevendra Hiwase, Peter Tan, James D'Rozario, et al.
Blood|September 2, 2020
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemiaNaranie Shanmuganathan, Ilaria S Pagani, David M Ross, et al.
International Journal of Hematology|March 25, 2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyMichele Baccarani, Brian J Druker, Susan Branford, et al.
Leukemia & Lymphoma|January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemiaMasa Lasica, Abbey Willcox, Kate Burbury, et al.
Leukemia|August 13, 2020
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responsesShady Adnan Awad, Olli Dufva, Aleksandr Ianevski, et al.
Journal of Psychopharmacology (Oxford, England)|August 16, 2008
Antipsychotics and hyperprolactinaemia: clinical recommendationsRobert C Peveler, David Branford, Leslie Citrome, et al.
Bjpsych Open|October 16, 2020
COVID-19 deaths in people with intellectual disability in the UK and Ireland: descriptive studyBhathika Perera, Richard Laugharne, William Henley, et al.
Blood Advances|January 4, 2018
<i>ASXL1</i> and <i>BIM</i> germ line variants predict response and identify CML patients with the greatest risk of imatinib failureJustine E Marum, David T Yeung, Leanne Purins, et al.
Leukemia|October 4, 2023
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemiaNicholas C P Cross, Thomas Ernst, Susan Branford, et al.
Pageof 48

Showing results (371-380 of 480) with videos related to

Sort By:
Pageof 48
Nature Communications|August 27, 2024
Neuromorphic overparameterisation and few-shot learning in multilayer physical neural networksKilian D Stenning, Jack C Gartside, Luca Manneschi, et al.
Leukemia Research|March 2, 2018
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift studyDevendra Hiwase, Peter Tan, James D'Rozario, et al.
Blood|September 2, 2020
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemiaNaranie Shanmuganathan, Ilaria S Pagani, David M Ross, et al.
International Journal of Hematology|March 25, 2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) studyMichele Baccarani, Brian J Druker, Susan Branford, et al.
Leukemia & Lymphoma|January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemiaMasa Lasica, Abbey Willcox, Kate Burbury, et al.
Leukemia|August 13, 2020
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responsesShady Adnan Awad, Olli Dufva, Aleksandr Ianevski, et al.
Journal of Psychopharmacology (Oxford, England)|August 16, 2008
Antipsychotics and hyperprolactinaemia: clinical recommendationsRobert C Peveler, David Branford, Leslie Citrome, et al.
Bjpsych Open|October 16, 2020
COVID-19 deaths in people with intellectual disability in the UK and Ireland: descriptive studyBhathika Perera, Richard Laugharne, William Henley, et al.
Blood Advances|January 4, 2018
<i>ASXL1</i> and <i>BIM</i> germ line variants predict response and identify CML patients with the greatest risk of imatinib failureJustine E Marum, David T Yeung, Leanne Purins, et al.
Leukemia|October 4, 2023
European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemiaNicholas C P Cross, Thomas Ernst, Susan Branford, et al.
Pageof 48